This inventor holds 4 USPTO granted patents. Top assignee: Eli Lilly and Company. Active years: 2009-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009-2013
Title: Walter Francis Prouty, Jr.: Innovator in Glucagon-Like Peptide 1 Compounds
Introduction
Walter Francis Prouty, Jr. is an accomplished inventor based in Indianapolis, Indiana. With four patents to his name, he has made significant contributions to the field of biochemistry, particularly in the development of glucagon-like peptide-1 (GLP-1) compounds. His work is driven by the goal of improving therapeutic options for various medical conditions.
Latest Patents
One of his most notable patents, titled "Process for Solubilizing Glucagon-Like Peptide 1 Compounds," describes a method for preparing a GLP-1 compound that can dissolve in aqueous solution at pH 7.4. This method focuses on transforming insoluble GLP-1 compounds into a soluble form, which is essential for their application in pharmaceuticals. The process involves dissolving the insoluble compounds in either an aqueous base or acid, followed by neutralization to avoid amino acid racemization. This innovative approach enhances the viability of GLP-1 compounds for therapeutic use.
Career Highlights
Walter currently works at Eli Lilly and Company, a prominent pharmaceutical firm known for its dedication to scientific advancements and innovative therapies. His role at the company allows him to advance his research and development efforts in peptide therapeutics, where he continues to build on his groundbreaking work in solubilization techniques.
Collaborations
Throughout his career, Walter has collaborated closely with Joseph Vincent Rinella, Jr. This partnership has fostered a fruitful interchange of ideas and expertise, contributing to the success of their joint projects in the realm of peptide research.
Conclusion
Walter Francis Prouty, Jr. stands out as a key innovator in the field of glucagon-like peptide-1 research. Through his patents and collaboration with industry experts, he continues to pave the way for new therapeutic possibilities. His work not only showcases his expertise but also reflects the ongoing innovations happening within the biopharmaceutical sector.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile